Irene A Whitney

US Patent:

20120135975, May 31, 2012

Filed:

May 14, 2007

Appl. No.:

12/227035

Inventors:

Vincent J. Colandrea - North Brunswick NJ, US
William K. Hagmann - Westfield NJ, US
Jeffrey J. Hale - Westfield NJ, US
Irene E. Whitney - New Haven CT, US

Assignee:

MERCK & CO., INC. - rAHWAY NJ

International Classification:

A61K 31/397
C07D 213/80
C07D 213/79
C07D 285/06
C07D 231/14
C07D 241/24
C07D 487/04
A61K 31/277
A61K 31/455
A61K 31/4402
A61K 31/4409
A61K 31/433
A61K 31/415
A61K 31/4965
A61K 31/42
A61K 31/519
A61K 31/4985
A61P 25/18
A61P 25/28
A61P 25/06
A61P 25/00
A61P 29/00
A61P 25/22
A61P 25/08
A61P 25/16
A61P 25/30
A61P 1/00
A61P 1/16
A61P 11/06
A61P 3/04
A61P 25/32
A61P 25/34
A61P 25/36
A61K 31/366
C07C 255/60

US Classification:

51421002, 558414, 546322, 546326, 548127, 5483741, 544406, 544281, 514522, 514356, 514357, 558416, 514361, 514406, 51425506, 514378, 5142593, 514249, 514460

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.